{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:39:09Z","timestamp":1792640349469,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-14049-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:04:55Z","timestamp":1784909095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceftazidime-avibactam as a polymyxin-sparing option for multidrug-resistant Gram-negative infections in children: a real-world comparative cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sevgi","family":"Aslan Tuncay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsen","family":"Akkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Celikboya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyhan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Parlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Canizci Erdemli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Dizi Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem Buyuktas","family":"Aytac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem Cagla","family":"Abaci Capar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Furkan","family":"Eser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makbule Nilufer","family":"Yalindag Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda","family":"Kepenekli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevliya","family":"Ocal Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"14049_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet. 2024;404:1199\u2013226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1.","journal-title":"Lancet"},{"key":"14049_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"14049_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions. Clin Microbiol Infect. 2012;18:268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"14049_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jpids\/piz085","volume":"9","author":"K Chiotos","year":"2020","unstructured":"Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatr Infect Dis Soc. 2020;9:56\u201366. https:\/\/doi.org\/10.1093\/jpids\/piz085.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"14049_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/jac\/dkae387","volume":"80","author":"G Avcu","year":"2025","unstructured":"Avcu G, Erci E, Bilen NM, et al. Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital. J Antimicrob Chemother. 2025;80:147\u201353. https:\/\/doi.org\/10.1093\/jac\/dkae387.","journal-title":"J Antimicrob Chemother"},{"key":"14049_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/aam.aam_209_21","volume":"22","author":"N Adel","year":"2023","unstructured":"Adel N, Khedr R, Elanany M, et al. Outcome and safety of colistin use in paediatric cancer patients with carbapenem-resistant Enterobacteriaceae bacteraemia at Children Cancer Hospital Egypt. Ann Afr Med. 2023;22:82\u20137. https:\/\/doi.org\/10.4103\/aam.aam_209_21.","journal-title":"Ann Afr Med"},{"key":"14049_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa with difficult-to-treat resistance. Clin Infect Dis. 2022;75:187\u2013212. https:\/\/doi.org\/10.1093\/cid\/ciac268.","journal-title":"Clin Infect Dis"},{"key":"14049_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae403.","journal-title":"Clin Infect Dis"},{"key":"14049_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/INF.0000000000002395","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Roilides E, Broadhurst H, et al. Safety and efficacy of ceftazidime-avibactam in the treatment of children > = 3 months to < 18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38:920\u20138. https:\/\/doi.org\/10.1097\/INF.0000000000002395.","journal-title":"Pediatr Infect Dis J"},{"key":"14049_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Broadhurst H, Cheng K, et al. Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children > = 3 months to < 18 years with complicated intra-abdominal infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38:816\u201324. https:\/\/doi.org\/10.1097\/INF.0000000000002392.","journal-title":"Pediatr Infect Dis J"},{"key":"14049_CR11","doi-asserted-by":"publisher","first-page":"piaf028","DOI":"10.1093\/jpids\/piaf028","volume":"14","author":"J Bradley","year":"2025","unstructured":"Bradley J, Roilides E, Tawadrous M, et al. Pharmacokinetics and safety of ceftazidime-avibactam in neonates and young infants: a phase 2a, multicentre prospective trial. J Pediatr Infect Dis Soc. 2025;14:piaf028. https:\/\/doi.org\/10.1093\/jpids\/piaf028.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"14049_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/antibiotics13070598","volume":"13","author":"M Garcia-Boyano","year":"2024","unstructured":"Garcia-Boyano M, Alos Diez M, Fernandez Tome L, et al. Ceftazidime-avibactam use in a case series of difficult-to-treat or recurrent infections in paediatric patients with complex chronic conditions: effectiveness and absence of resistance development. Antibiot (Basel). 2024;13:598. https:\/\/doi.org\/10.3390\/antibiotics13070598.","journal-title":"Antibiot (Basel)"},{"key":"14049_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/children11060664","volume":"11","author":"AR Araujo da Silva","year":"2024","unstructured":"Araujo da Silva AR, Quijada R. Use of ceftazidime-avibactam in children admitted to paediatric intensive care units. Child (Basel). 2024;11:664. https:\/\/doi.org\/10.3390\/children11060664.","journal-title":"Child (Basel)"},{"key":"14049_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/antibiotics13111037","volume":"13","author":"R Garcia Romero","year":"2024","unstructured":"Garcia Romero R, Fresan-Ruiz E, Guitart C, et al. The use of ceftazidime-avibactam in a paediatric intensive care unit: an observational prospective study. Antibiot (Basel). 2024;13:1037. https:\/\/doi.org\/10.3390\/antibiotics13111037.","journal-title":"Antibiot (Basel)"},{"key":"14049_CR15","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10096-024-04948-y","volume":"43","author":"OO Gundeslioglu","year":"2024","unstructured":"Gundeslioglu OO, Haytoglu Z, Gumus HH, et al. Clinical experience with ceftazidime-avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children. Eur J Clin Microbiol Infect Dis. 2024;43:2361\u20139. https:\/\/doi.org\/10.1007\/s10096-024-04948-y.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"14049_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/INF.0000000000002344","volume":"38","author":"E Iosifidis","year":"2019","unstructured":"Iosifidis E, Chorafa E, Agakidou E, et al. Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children younger than 5 years. Pediatr Infect Dis J. 2019;38:812\u20135. https:\/\/doi.org\/10.1097\/INF.0000000000002344.","journal-title":"Pediatr Infect Dis J"},{"key":"14049_CR17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10096-025-05044-5","volume":"44","author":"N Khoshdel","year":"2025","unstructured":"Khoshdel N, Noursalehigarakani M, Seghatoleslami ZS, et al. Efficacy of ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2025;44:767\u201378. https:\/\/doi.org\/10.1007\/s10096-025-05044-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"14049_CR18","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40121-024-00999-y","volume":"13","author":"RK Shields","year":"2024","unstructured":"Shields RK, Horcajada JP, Kamat S, et al. Ceftazidime-avibactam in the treatment of patients with bacteraemia or nosocomial pneumonia: a systematic review and meta-analysis. Infect Dis Ther. 2024;13:1639\u201364. https:\/\/doi.org\/10.1007\/s40121-024-00999-y.","journal-title":"Infect Dis Ther"},{"key":"14049_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.12669\/pjms.41.3.9978","volume":"41","author":"N Mehdi","year":"2025","unstructured":"Mehdi N, Majeed N, Ali F, et al. High ceftazidime-avibactam resistance rate in carbapenem-resistant Gram-negative organisms in Pakistan\u2019s paediatric population. Pak J Med Sci. 2025;41:788\u201391. https:\/\/doi.org\/10.12669\/pjms.41.3.9978.","journal-title":"Pak J Med Sci"},{"key":"14049_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12879-026-12589-z","volume":"26","author":"J Merida-Vieyra","year":"2026","unstructured":"Merida-Vieyra J, Aquino-Andrade A, Tapia-Reyes A, et al. Microbiological characterization and clinical outcomes of carbapenem-resistant Enterobacterales infections in a paediatric hospital in Mexico. BMC Infect Dis. 2026;26:330. https:\/\/doi.org\/10.1186\/s12879-026-12589-z.","journal-title":"BMC Infect Dis"},{"key":"14049_CR21","unstructured":"Pfizer PFE, Ila\u00e7lar\u0131. A.\u015e. ZAVICEFTA 2\u00a0g\/0.5\u00a0g inf\u00fczyonluk \u00e7\u00f6zelti haz\u0131rlamak i\u00e7in toz: k\u0131sa \u00fcr\u00fcn bilgisi. Initial marketing authorization date: 16 October 2019. Accessed 9 Mar 2026."},{"key":"14049_CR22","unstructured":"Sosyal G\u00fcvenlik Kurumu. Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011f. Resmi Gazete. 2021;31468. Accessed 9 Mar 2026."},{"key":"14049_CR23","unstructured":"Sosyal G\u00fcvenlik Kurumu. Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011f. Resmi Gazete. 2026;33140. Accessed 9 Mar 2026."},{"key":"14049_CR24","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296.","journal-title":"PLoS Med"},{"key":"14049_CR25","unstructured":"Centers for Disease Control and Prevention. 2024 National Healthcare Safety Network Patient Safety Component Manual. https:\/\/www.cdc.gov\/nhsn\/pdfs\/validation\/2024\/pcsmanual_2024.pdf. Accessed 4 May 2026."},{"key":"14049_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.2","volume":"2","author":"Kidney Disease","year":"2012","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138. https:\/\/doi.org\/10.1038\/kisup.2012.2.","journal-title":"Kidney Int Suppl"},{"key":"14049_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315. https:\/\/doi.org\/10.1038\/clpt.2011.58.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14049-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:03:07Z","timestamp":1792638187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14049"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14049-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Marmara University Faculty of Medicine Clinical Research Ethics Committee (09.2024.616) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study and the use of existing clinical records.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain individual person\u2019s identifiable data, images or videos.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During manuscript preparation, an AI-based language and formatting tool was used for editorial restructuring and language refinement. The authors reviewed and edited all AI-assisted output and take full responsibility for the final content of the manuscript.","order":3,"name":"Ethics","label":"Use of artificial intelligence tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1854"}}